Overview

Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of PAD-regimen and TAD-regimen in newly diagnosed multiple myeloma(MM).
Phase:
Phase 4
Details
Lead Sponsor:
Second Military Medical University
Collaborators:
Air Force Military Medical University, China
Beijing Jishuitan Hospital
First Affiliated Hospital, Sun Yat-Sen University
Fourth Military Medical University
Harbin Hematology and Oncology Institute
Harbin Institute of Hematology and Oncology
Institute of Hematology & Blood Diseases Hospital
Peking University People's Hospital
Union hospital of Fujian Medical University
Xiangya Hospital of Central South University
Zhejiang University
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Pirarubicin
Thalidomide